Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02834013 · ClinicalTrials.gov registry record · Phase 2

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

A Phase 2 study of Adenoid Cystic Carcinoma and Angiosarcoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
818
Enrollment target
20
Study locations

NCT02834013: Active Phase 2 study of Adenoid Cystic Carcinoma and Angiosarcoma, sponsored by National Cancer Institute (NCI).

NCT02834013 is a Phase 2 study of Adenoid Cystic Carcinoma and Angiosarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 818 participants, above the 77-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (962% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02834013, a Phase 2 study of Adenoid Cystic Carcinoma and Angiosarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
818 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer \[NPC\], and squamous cell carcinoma of the head and neck \[SCCHN\]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell t

Primary Outcome

Defined as confirmed and unconfirmed complete and partial response. Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Conditions Studied

Adenoid Cystic Carcinoma Angiosarcoma Adrenal Cortical Carcinoma Acinar Cell Carcinoma Adrenal Gland Pheochromocytoma Anal Canal Neuroendocrine Carcinoma Anal Canal Undifferentiated Carcinoma Apocrine Neoplasm Appendix Mucinous Adenocarcinoma Bartholin Gland Transitional Cell Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Echocardiography Test
  • BIOLOGICAL Ipilimumab

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage
  • Fairbanks Memorial Hospital - Fairbanks

Arkansas

  • Highlands Oncology Group - Fayetteville - Fayetteville
  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
  • University of Arkansas for Medical Sciences - Little Rock
  • Highlands Oncology Group - Rogers - Rogers

Arizona

  • CTCA at Western Regional Medical Center - Goodyear
  • Kingman Regional Medical Center - Kingman
  • Cancer Center at Saint Joseph's - Phoenix

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • University of South Alabama Mitchell Cancer Institute - Mobile

Trial Details

FieldValue
Enrollment Target 818 participants
Start Date 2017-01-30
Est. Completion 2026-05-01
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02834013 still lists

NCT02834013 is an interventional study that assigns participants to a tested intervention. The registered 818 participants enrollment target is mid-sized for trials with a published cap, above the 77-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (962% higher).

The record links to 10 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02834013 names 20 study sites across 4 states, led by Alaska, Arkansas, Arizona.

Frequently Asked Questions

What is clinical trial NCT02834013 about?

NCT02834013 is a clinical study titled "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors". This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This tri...

What is the current status of trial NCT02834013?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 818 participants. The study started on 2017-01-30. Estimated completion is 2026-05-01.

What conditions does trial NCT02834013 study?

This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Angiosarcoma, Adrenal Cortical Carcinoma, Acinar Cell Carcinoma, Adrenal Gland Pheochromocytoma.

What interventions are being tested in trial NCT02834013?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Echocardiography Test (PROCEDURE), Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02834013?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02834013 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenoid Cystic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02834013's enrollment target sits among peer trials

818 1st of 16 higher than 16 of 16 other Adenoid Cystic Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adenoid Cystic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04846959 · 818 participants

    Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

  • NCT04028687 · 820 participants

    MDR - PMCF Study for Taperloc Complete Stems

  • NCT04613440 · 820 participants · NA

    FaCT Trial (Facilitated Cascade Testing Trial)

  • NCT04910269 · 820 participants · Phase 3

    Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02834013, the US trial registry maintained by the National Library of Medicine. NCT02834013 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.